ARS Pharmaceuticals, Inc.
SPRY
$8.25
-$0.05-0.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -67.56% | 1,471.62% | 3,043.40% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -67.56% | 1,471.62% | 3,043.40% | -- | -- |
| Cost of Revenue | 146.58% | 141.28% | 30.79% | -22.70% | 14.34% |
| Gross Profit | -77.64% | 973.90% | 204.72% | 175.03% | 2,529.17% |
| SG&A Expenses | 68.93% | 287.69% | 507.25% | 416.51% | 420.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 76.60% | 259.81% | 299.82% | 242.25% | 285.14% |
| Operating Income | -187.86% | -144.58% | -210.39% | -181.81% | 561.54% |
| Income Before Tax | -182.44% | -167.41% | -258.60% | -229.77% | 800.64% |
| Income Tax Expenses | -127.78% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -182.76% | -167.41% | -258.60% | -229.77% | 796.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -182.76% | -167.41% | -258.60% | -229.77% | 796.62% |
| EBIT | -187.86% | -144.58% | -210.39% | -181.81% | 561.54% |
| EBITDA | -186.92% | -143.02% | -208.93% | -179.93% | 562.37% |
| EPS Basic | -181.39% | -162.66% | -252.90% | -224.37% | 787.27% |
| Normalized Basic EPS | -164.86% | -162.66% | -252.97% | -187.80% | 720.93% |
| EPS Diluted | -199.74% | -162.66% | -252.90% | -224.37% | 663.67% |
| Normalized Diluted EPS | -179.40% | -162.66% | -252.97% | -187.80% | 607.27% |
| Average Basic Shares Outstanding | 1.67% | 1.83% | 1.58% | 1.63% | 1.32% |
| Average Diluted Shares Outstanding | -16.93% | 1.83% | 1.58% | 1.63% | 24.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |